Breakthrough Five-Year Outcomes: Vamorolone Shows Promising Positive Results in Duchenne Muscular Dystrophy Treatment

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

Ad hoc announcement pursuant to Art. 53 LR

Breakthrough Five-Year Outcomes: Vamorolone Shows Promising Positive Results in Duchenne Muscular Dystrophy Treatment

Archyde Vamorolone Demonstrates Sustained Benefit in Duchenne Muscular Dystrophy, New Data Reveal New Findings from the Guardian study indicate that Vamorolone, a novel corticosteroid treatment for Duchenne muscular dystrophy (Dmd), is… You can read the full story here: Breakthrough Five-Year Outcomes: Vamorolone Shows Promising Positive Results in Duchenne Muscular Dystrophy Treatment.

Santhera reports promising long-term data for AGAMREE in Duchenne muscular dystrophy

Early treatment with vamorolone shows sustained efficacy and improved safety profile